Prior to its cancelation due to the COVID-19 pandemic, data scheduled to be presented at the American Academy of Neurology (AAN) 2020 Annual Meeting from the TELECAST trial suggest that telestroke care can provide benefits for patients by improving access. The analysis was conducted by Matthew Ronck, MD, vascular neurology fellow, University of Minnesota, et al.
Although the findings might be somewhat anticipated based on what literature already suggest, for Jeremy Payne, MD, PhD, director, Stroke Center, Banner-University Medical Center, data are like these are necessary to help improve the state of telestroke care. Payne, who was not part of the study, described to NeurologyLive in an interview much of what has held the field back in his experience.
Payne also shared his thoughts on how the ongoing pandemic may help push the progress in telestroke along—a feeling that has been echoed in a number of specialties—particularly in its attempts to overcome the obstacles faced by factors such as reimbursement and HIPAA compliance.
